MORE controversy about using pioglitazone (Actos, etc) for type 2 diabetes

October 2012

New concerns about bladder cancer mean you'll hear MORE controversy about using pioglitazone (Actos, etc) for type 2 diabetes.

Pioglitazone is off the market in France while authorities investigate. Regulators in other countries are also assessing its risks.

We're advising pharmacists and prescribers to keep the risk of bladder cancer in perspective.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Psychiatry mix-ups among diclofenac products
Influenza you'll see a LESS concentrated Tamiflu (oseltamivir) suspension and an INTRADERMAL influenza vaccine
Substance Use Disorder more people abusing Suboxone tabs
Diabetes Meds MORE controversy about using pioglitazone (Actos, etc) for type 2 diabetes
Lice about "noninsecticide" products (Nyda, Resultz, Zap, etc) for treating head lice
Antipsychotics whether it's okay to combine antipsychotics
Depression more emphasis on treating depression in heart patients
Statins whether statins (lovastatin, simvastatin, atorvastatin, etc) increase the risk of cataracts
Antidepressants more prescriptions for Cymbalta (duloxetine)
Infectious Diseases You'll see more attention on West Nile virus
Hypertension buzz about when drugs should be started in patients with MILD hypertension
Communication helping patients who don't speak the same language as you or your pharmacist